Plus   Neg

Stock Alert: MyoKardia Surges 60% On Bristol Myers Acquisition

Shares of MyoKardia, Inc. (MYOK) soared nearly 60% on Monday morning after Bristol Myers Squibb (BMY) agreed to buy MyoKardia for $13.1 billion.

MYOK is currently trading at $221.22, up $81.62 or 58.47%, on the Nasdaq.

MyoKardia is a clinical-stage biopharmaceutical company developing targeted therapies for the treatment of serious cardiovascular diseases. Bristol Myers agreed to acquire MyoKardia for $225 per share in cash.

MyoKardia's lead candidate is Mavacamten, which successfully completed a phase III trial in obstructive hypertrophic cardiomyopathy recently. A New Drug Application for Mavacamten in the treatment of obstructive hypertrophic cardiomyopathy is expected to be submitted to the FDA in the first quarter of 2021.

Bristol Myers Squibb expects MyoKardia's acquisition to strengthen and expand its cardiovascular franchise. The deal is expected to close during the fourth quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Data giant S&P Global Inc. has agreed to acquire information and analytics company IHS Markit Ltd. in an all-stock deal, the two companies said Monday. The deal values IHS Markit at an enterprise value of $44 billion, including $4.8 billion of net debt. Shares of IHS Markit are gaining almost 6 percent following the news. The deal is the biggest in 2020. Moderna, Inc. (MRNA) said it will apply for an Emergency Use approval of its Covid vaccine as the latest study showed that the vaccine candidate is 94.1% effective to prevent Covid-19. The company said there have been no serious safety concerns identified. The company will file for an Emergency... Vegpro International is recalling Fresh Attitude baby spinach citing potential to be contaminated with Salmonella, according to the U.S. Food and Drug Administration. The recall involves Fresh Attitude baby spinach of 5oz with best before dates of December 4 & 5; and 11oz with best before date of December 4.
Follow RTT